Sanofi to acquire Provention Bio for $2.9bn 13-Mar-2023 By Rachel Arthur Sanofi will acquire US-based Provention Bio: gaining Tzield (teplizumab-mzwv), which was approved by the FDA last year as the first and only therapy to delay the onset of Stage 3 type 1 diabetes.
